Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QoLESS AZA-AMLE
2010-019710-24Phase 3Terminated
- Sponsor
- Qol-one
- Start
- Jun 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Azacitidine with Placebo (2 arms). Primary endpoints: Overall survival at 2 years, Disease-free survival at 2 years and 1 more. Started Jun 2010; status: terminated.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-019710-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019710-24.